Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03671590 |
| Title | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | TG Therapeutics, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | POL | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| TG Therapeutics Investigational Trial Site | East Melbourne | Victoria | Australia | Details | ||
| TG Therapeutics Investigational Trial Site | Fitzroy | Victoria | Australia | Details | ||
| TG Therapeutics Investigational Trial Site | Nedlands | Western Australia | Australia | Details | ||
| TG Therapeutics Investigational Trial Site | Adelaide | Australia | Details | |||
| TG Therapeutics Investigational Trial Site | Kraków | 30-510 | Poland | Details | ||
| TG Therapeutics Investigational Trial Site | Lublin | 20-090 | Poland | Details | ||
| TG Therapeutics Investigational Trial Site | Warszawa | 02-781 | Poland | Details | ||
| TG Therapeutics Investigational Trial Site | Wrocław | 50-367 | Poland | Details |